Eric J. Bow

13.2k total citations · 5 hit papers
75 papers, 8.3k citations indexed

About

Eric J. Bow is a scholar working on Oncology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eric J. Bow has authored 75 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 42 papers in Epidemiology and 35 papers in Infectious Diseases. Recurrent topics in Eric J. Bow's work include Neutropenia and Cancer Infections (48 papers), Antifungal resistance and susceptibility (30 papers) and Fungal Infections and Studies (27 papers). Eric J. Bow is often cited by papers focused on Neutropenia and Cancer Infections (48 papers), Antifungal resistance and susceptibility (30 papers) and Fungal Infections and Studies (27 papers). Eric J. Bow collaborates with scholars based in Canada, United States and France. Eric J. Bow's co-authors include Kenneth V. I. Rolston, John R. Wingard, Issam Raad, Craig A. Mullen, James I. Ito, Alison G. Freifeld, Jo‐Anne H. Young, Michael Boeckh, Kent A. Sepkowitz and Walter T. Hughes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eric J. Bow

75 papers receiving 8.1k citations

Hit Papers

Clinical Practice Guideli... 2002 2026 2010 2018 2011 2002 2011 2018 2015 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
    2011 2.3k citations Alison G. Freifeld, Eric J. Bow et al. Clinical Infectious Diseases profile →
  2. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
    2002 1.4k citations Eric J. Bow, Kenneth V. I. Rolston et al. Clinical Infectious Diseases profile →
  3. Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
    2011 507 citations Alison G. Freifeld, Eric J. Bow et al. Clinical Infectious Diseases profile →
  4. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
    2018 356 citations Eric J. Bow, Kenneth V. I. Rolston et al. Journal of Clinical Oncology profile →
  5. Combination Antifungal Therapy for Invasive Aspergillosis
    2015 333 citations Haran T. Schlamm, Eric J. Bow et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Eric J. Bow 5.3k 3.7k 3.1k 2.2k 930 75 8.3k
Alison G. Freifeld 3.7k 0.7× 3.7k 1.0× 2.8k 0.9× 1.6k 0.7× 699 0.8× 97 7.4k
James C. Wade 2.7k 0.5× 3.0k 0.8× 3.1k 1.0× 2.2k 1.0× 553 0.6× 90 9.6k
Jo‐Anne H. Young 3.8k 0.7× 4.8k 1.3× 3.9k 1.2× 1.2k 0.6× 463 0.5× 96 9.0k
Kenneth V. I. Rolston 7.6k 1.4× 4.6k 1.2× 3.3k 1.1× 4.2k 1.9× 1.6k 1.8× 211 13.1k
Walter T. Hughes 3.1k 0.6× 6.5k 1.8× 4.3k 1.4× 1.2k 0.6× 724 0.8× 216 10.3k
Lowell S. Young 2.4k 0.5× 2.8k 0.8× 2.0k 0.6× 1.3k 0.6× 541 0.6× 123 6.8k
James I. Ito 2.7k 0.5× 2.4k 0.7× 2.0k 0.7× 1.1k 0.5× 446 0.5× 57 5.4k
Elio Castagnola 2.2k 0.4× 3.0k 0.8× 2.6k 0.8× 863 0.4× 389 0.4× 300 6.6k
Jerry L. Shenep 2.4k 0.5× 2.1k 0.6× 1.1k 0.4× 1.4k 0.6× 549 0.6× 109 5.8k
J. Peter Donnelly 3.5k 0.7× 6.2k 1.7× 6.6k 2.1× 797 0.4× 338 0.4× 178 12.2k

Countries citing papers authored by Eric J. Bow

Since Specialization
Citations

This map shows the geographic impact of Eric J. Bow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Bow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Bow more than expected).

Fields of papers citing papers by Eric J. Bow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Bow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Bow. The network helps show where Eric J. Bow may publish in the future.

Co-authorship network of co-authors of Eric J. Bow

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Bow. A scholar is included among the top collaborators of Eric J. Bow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Bow. Eric J. Bow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Young, Jo‐Anne H., David R. Andes, Monica I. Ardura, et al.. (2024). Modeling Invasive Aspergillosis Risk for the Application of Prophylaxis Strategies. Open Forum Infectious Diseases. 11(3). ofae082–ofae082. 12 indexed citations
2.
Cuvelier, Geoff D.E., Kristjan Paulson, & Eric J. Bow. (2023). Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections. Transplant Infectious Disease. 25(S1). e14101–e14101. 2 indexed citations
3.
Lambert, Pascal, Eric J. Bow, Piotr Czaykowski, et al.. (2023). Evaluation of the Impact of the Urgent Cancer Care Clinic on Emergency Department Visits, Primary Care Clinician Visits, and Hospitalizations in Winnipeg, Manitoba. Current Oncology. 30(7). 6771–6785. 3 indexed citations
4.
5.
Kumar, Anand, Anand Kumar, Ryan Zarychanski, et al.. (2018). Fungicidal versus fungistatic therapy of invasive Candida infection in non-neutropenic adults: a meta-analysis. Mycology: An International Journal on Fungal Biology. 9(2). 116–128. 29 indexed citations
6.
Bow, Eric J., David J. Vanness, Monica A. Slavin, et al.. (2015). Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infectious Diseases. 15(1). 128–128. 44 indexed citations
7.
Laverdière, Michél, Eric J. Bow, Coleman Rotstein, et al.. (2014). Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Canadian Journal of Infectious Diseases and Medical Microbiology. 25(6). 327–343. 57 indexed citations
8.
Bow, Eric J.. (2013). There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. Journal of Antimicrobial Chemotherapy. 68(3). 492–495. 34 indexed citations
9.
Freifeld, Alison G., Eric J. Bow, Kent A. Sepkowitz, et al.. (2011). Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 52(4). e56–e93. 2328 indexed citations breakdown →
10.
Bow, Eric J.. (2011). Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Current Opinion in Infectious Diseases. 24(6). 545–553. 91 indexed citations
11.
Ostrosky‐Zeichner, Luis, Bart Jan Kullberg, Eric J. Bow, et al.. (2010). Early treatment of candidemia in adults: a review. Medical Mycology. 49(2). 113–120. 79 indexed citations
12.
Bow, Eric J., Gerald A. Evans, Jeff Fuller, et al.. (2010). Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology. 21(4). e122–50. 43 indexed citations
13.
Bow, Eric J.. (2005). Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clinical Microbiology and Infection. 11. 24–29. 31 indexed citations
14.
Doucette, Karen, et al.. (2003). Disseminated Zygomycosis: A Rare Cause of Infection in Patients With Hematologic Malignancies. The Journal of Trauma: Injury, Infection, and Critical Care. 55(3). 568–570. 4 indexed citations
15.
Madani, Tariq A., et al.. (1998). Value of routine procurement of Isolator in addition to BacT/Alert blood cultures in febrile neutropenic patients with acute myeloid leukemia. 9(5). 287–293. 1 indexed citations
16.
Bow, Eric J.. (1998). Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. Journal of Antimicrobial Chemotherapy. 41(suppl 4). 1–5. 55 indexed citations
17.
Bow, Eric J., et al.. (1997). Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.. Journal of Clinical Oncology. 15(6). 2254–2261. 78 indexed citations
18.
19.
Bow, Eric J., et al.. (1995). Invasive Fungal Disease in Adults Undergoing Remission-Induction Therapy for Acute Myeloid Leukemia: The Pathogenetic Role of the Antileukemic Regimen. Clinical Infectious Diseases. 21(2). 361–369. 145 indexed citations
20.
Bow, Eric J., et al.. (1983). Coexistence of Double Gammopathy (IgM Kappa and IgM Lambda) in the Serum of a Single Individual with Chronic Lymphocytic Leukemia. Acta Haematologica. 69(1). 23–31. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alison G. Freifeld Breakdown of academic impact, for papers by James C. Wade Breakdown of academic impact, for papers by Jo‐Anne H. Young Breakdown of academic impact, for papers by Kenneth V. I. Rolston Breakdown of academic impact, for papers by Walter T. Hughes Breakdown of academic impact, for papers by Lowell S. Young Breakdown of academic impact, for papers by James I. Ito Breakdown of academic impact, for papers by Elio Castagnola Breakdown of academic impact, for papers by Jerry L. Shenep Breakdown of academic impact, for papers by J. Peter Donnelly
Rankless by CCL
2026